Revolution Medicines (RVMD) Return on Capital Employed (2020 - 2026)

Revolution Medicines' Return on Capital Employed history runs 7 years deep, the most recent figure standing at 21.94% for Q1 2026.

• In Q1 2026, Return on Capital Employed rose 1233.0% year-over-year to 21.94%; the TTM figure through Mar 2026 stood at 21.94% (up 1233.0% YoY), while the FY2025 annual figure was 10.97%, up 2116.0% from the prior year.
• Return on Capital Employed was 21.94% for Q1 2026 at Revolution Medicines, down from 11.8% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 11.8% in Q4 2025 to a low of 49.5% in Q3 2025.
• Historically, Return on Capital Employed has averaged 33.83% across 5 years, with a median of 34.27% in 2025.
• The sharpest annual moves came in 2022 and 2025: Return on Capital Employed tumbled 1883 bps in 2022, then surged 2273 bps in 2025.
• A 5-year view of Return on Capital Employed shows it stood at 34.12% in 2022, then retreated by 4 bps to 35.33% in 2023, then advanced by 2 bps to 34.53% in 2024, then soared by 66 bps to 11.8% in 2025, then plunged by 86 bps to 21.94% in 2026.
• The last three Return on Capital Employed figures came in at 21.94% (Q1 2026), 11.8% (Q4 2025), and 49.5% (Q3 2025), per Business Quant data.